Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers  by de Jonge, Hugo R. et al.
www.elsevier.com/locate/jcf
Journal of Cystic Fibrosis 3 (2004) 159–163Ex vivo CF diagnosis by intestinal current measurements (ICM) in small
aperture, circulating Ussing chambers
Hugo R. De Jongea,*, Manfred Ballmannb, Henk Veezec, Inez Bronsvelda, Frauke Stankeb,
Burkhard Tu¨mmlerb, Maarten Sinaasappela
aDepartments of Paediatric Gastroenterology and Biochemistry , Erasmus University Medical Centre, P.O. Box 1738, Rotterdam, 3000DR The Netherlands
bKlinische Forschergruppe, OE 6710, Medizinische Hochschule Hannover, Germany
c IJsselland Hospital, P.O. Box 690, 2900 AR, Capelle a/d Ijssel, The NetherlandsAvailable onlineAbstract
Intestinal current measurements (ICM) on rectal suction biopsies are a tool for the ex vivo diagnosis of classical and atypical cystic fibrosis
(CF). We present the basic ICM protocol, typical tracings and their interpretation. The ICM technique allows the registration of CF-induced
changes in electrogenic transepithelial ion transport (Cl, HCO3
, K+) in a Cl secretory epithelium, and on the basis of pharmacological criteria,
is able to discriminate between CFTR-mediated Cl secretion and secretion through alternative anion channels. ICM is particularly useful for
the classification of individuals with CF-like clinical features with equivocal sweat test values and/or no or one identifiable CFTR mutation.
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Intestinal current measurements (ICM) on rectal suction forskolin and 8-Br-cAMP; inhibition by 4,4V-diisothiocya-
biopsies in ‘‘micro’’-Ussing chambers were introduced
more than a decade ago by the Rotterdam CF research
group as a new ex vivo diagnostic method for CF [1,2].
Since then this electrophysiological technique has not only
proven its value in the fine-diagnosis of patients with mild
or subclinical symptoms of CF and borderline sweat test
results (Cl 30–60 mM) but has also been successfully
applied in genotype–phenotype studies to monitor the
influence of CF modifier genes on the manifestation of
the basic defect at the intestinal level (European CF Twin
And Sibling Study [3,4]), as well as to document the
presence of CFTR-mediated Cl secretion in a subgroup of
F508del homozygous CF patients [3]. The ICM technique
allows the direct registration of CF-induced changes in
electrogenic transepithelial ion transport (Cl, HCO3
, K+)
in a Cl secretory epithelium, and on the basis of phar-
macological criteria (e.g., activation by the cAMP agonist1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.05.034
Abbreviations: ClC channel, Ca2+-dependent Cl channel; DIDS, 4,4V-
diisothiocyanatostilbene-2,2V-disulfonic acid; ENaC, epithelial Na+ chan-
nel; IC, intestinal current; ICM, intestinal current measurements; Isc, short
circuit current; M, mucosal; ORCC, outwardly rectifying Cl channel; PD,
potential difference; PS, pancreatic sufficient; S, serosal.
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E-mail address: h.dejonge@erasmusmc.nl (H.R. De Jonge).natostilbene-2,2V-disulfonic acid, DIDS), is able to dis-
criminate between CFTR-mediated Cl secretion and
secretion through alternative, DIDS-sensitive anion chan-
nels. However the technique requires rather specialized
equipment and a well-trained and skilful technician and
therefore does not lend itself for routine application outside
a CF expertise centre.1. Ussing chamber design
As described recently by M Hug in his excellent review of
the Ussing chamber technique [5], there are currently two
types of micro-Ussing chambers in use for ICM studies: the
re-circulating chamber [1,2] and the continuously perfused
chamber [6–8]. The Rotterdam protocol for ICM is tailored
to the re-circulating chamber, in which oxygenation and
recirculation of the serosal (S) and mucosal (M) bath fluids
is maintained by airlifts, and the tissue is short-circuited
by voltage-clamp. Clear advantages of this design include:
(1) the use of a small bath volume (1.5 ml on both sides),
allowing the testing of rather precious drugs and biochem-
icals; (2) a reduced risk of extensive depletion of endoge-
nous regulatory factors, e.g. prostaglandins, which mighted by Elsevier B.V. All rights reserved.
Fig. 1. (A) Micro-Ussing chamber. (B) Mounting plates
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control biopsies [6]; (3) strict temperature control without
the need of an additional water jacket heating system. Sub-
stances are added in a sequential manner, and persist in the
bath until the end of the experiment. Washing out substances
can be done by repeated replacement of the bath fluid in the
upper reservoirs, but is relatively time-consuming. It is
therefore avoided in the standard protocol, considering the
limited time period (f 1–1.5 h) before the current responses
drop as the result of diminished tissue viability.2. Equipment for ICM on human rectal biopsies
2.1. Specifications of the chamber,1
Two half-chambers are connected by guiding pins
and compressed by Teflon screws; recirculating baths (1.51 Technical details of the design available on request to the
corresponding authorml volume), airlift system; voltage electrodes: calomel
(K401, Radiometer, Copenhagen, Denmark connected to
the bath by KCl-agar bridges; current electrodes: plati-
num; bath temperature kept at 37jC by water jackets
surrounding the fluid reservoirs and connected to a
recirculating waterbath; bath continuously gassed with
carbogen gas (95% O2/5% CO2); composition bath fluid
(Meyler buffer): 10 mM Hepes, 0.3 mM Na2HPO4,
0.4 mM NaH2PO4, 1.0 mM MgCl2, 1.3 mM CaCl2, 4.7
mM KCl, 105 mM NaCl, 20.2 mM NaHCO3, pH 7.4
(Fig. 1).
2.2. Current/voltage clamp equipment and digital data
acquisition
DVC-1000 Voltage/Current Clamp, two-channel (World
Precision Instruments, WPI, Berlin, Germany); DAM-50
Differential Amplifier (WPI); Digidata 1322A: analog/dig-
ital converter, 16-bits data acquisition system, including
AxoScope software (Axon Instruments, Union City, CA,
USA); PC with SCSI card; Printer.
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used to obtain a continuous recording of the short circuit
current (Isc). Periodically the tissue resistance was calculat-
ed from the change in potential difference (PD) resulting
from by a brief shift (2 s) to the current clamp mode of the
amplifier, and was corrected for the fluid resistance between
the potential sensing electrodes. Prior to tissue insertion, the
offset voltage generated by unequilibrated electrodes was
corrected manually.3. Mounting of the tissue
Rectal biopsies (F 3–4 mm; preferably two per patient
to allow duplicate measurements, provided that two Ussing
chambers are available), freshly obtained with a suction
biopsy device (Medicon, Tuttlingen, Germany), are soaked
into ice-cold PBS (1.5 mM KH2PO4; 3.2 mM Na2HPO4; 0.5
mM MgCl2; 0.9 mM CaCl2; 2.7 mM KCl; 137 mM NaCl)
and immediately taken to the laboratory. The biopsy spec-
imen is spread over the central, non-conical opening of the
larger mounting disk, convex side ( =M side) up (F 1.2
mm; exposed area 1.13 mm2). The smaller disk, containing
a central conical opening to prevent mucus obstruction, is
then brought into position by two guiding pins and com-
pressed by the two halves of the Ussing chamber. The tissue
is allowed 10–20 min to recover and to reach a stable
baseline. During this period, glucose (10 mM) is added as
an energy source both on the M and S sides.Fig. 2. Recordings of short circuit currents (Isc). ICM recordings of a non-
CF control (A), F508del homozygotes (B–D) and a pancreatic sufficient
(PS) patient carrying the CFTR mutation genotype 2183-AA!G/unknown
(E). Secretagogues applied as specified in the basic protocol are indicated
by arrows: amiloride (1), indomethacin (2), carbachol (3), cAMP/forskolin
(4), DIDS (5) and histamine (6). All tracings are normalised with respect to
the orientation based on the response to amiloride: a decrease in Isc, i.e. a
downward response defines the direction of the reversed response, and an
increase in Isc, i.e. an upward response, defines the direction of residual
chloride secretion upon the addition of carbachol, cAMP/forskolin or
histamine. (A) Non-CF control, with a large increase in Isc upon addition of
carbachol and histamine representing apical Cl secretion. (B) Typical CF
patient in whom carbachol, cAMP/forskolin, and histamine did not evoke
Cl exchange across the apical membrane. The reversed response implies
apical K+ efflux. Note not only the difference in direction of the Isc
response compared with control, but also the difference in scale. (C) CF4. Standard protocol for sequential addition of
compounds
After equilibration, the following compounds were
added in a standardized order to the M or S side of the
tissue:(a) amiloride (0.01 mM, M), to inhibit amiloride-
sensitive electrogenic Na+ absorption; (b) indomethacin
(0.01 mM, M+S), to reduce basal Cl secretion caused
by endogenous production of prostaglandins; (c) carbachol
(0.1 mM, S), to initiate the cholinergic Ca+- and protein
kinase C-linked Cl secretion; (d) forskolin (0.01 mM, S) +
8-Br-cAMP (1 mM, M+ S), to further activate cAMP-
dependent Cl channels such as CFTR and the outwardly
rectifying Cl channel (ORCC); (e) DIDS (0.2 mM, M),
to inhibit DIDS-sensitive, non-CFTR Cl channels like
the Ca2 +-dependent Cl (CaCC ) channels; (f) histamine
(0.5 mM, S), to reactivate the Ca2 + dependent secretory
pathway and to measure the DIDS-insensitive component
of Ca2 + dependent Cl secretion.
patient with residual Cl transport that is not influenced by the presence of
DIDS: carbachol, cAMP/forskolin, and histamine evoke residual Cl
secretion. (D) CF patient with DIDS-sensitive residual Cl secretion, which
is characterized by an increase in Isc in response to carbachol and cAMP/
forskolin but a decrease in Isc upon stimulation with histamine in the
presence of DIDS. (E) PS CF patient showing DIDS-insensitive residual
Cl secretion stimulated by carbachol, cAMP/forskolin and histamine.5. Diagnostic criteria for CF
The direction and magnitude of the Isc response to
carbachol and histamine are used as the principal diagnosticcriterion in ICM. From the reference values determined
at the Sophia Children Hospital in Rotterdam it is inferred
that a DIsc response >10 AA/cm2 points to a normal
functioning of CFTR, whereas a value below this threshold
Fig. 3. ICM recordings of diagnostic cases: CF-like disease in patients with
no identified CFTR mutation. Application of secretagogues and normali-
zation of tracings A, B, D as in Fig. 2. For tracing C, open-circuit and short-
circuit recordings are shown in parallel (1, application of amiloride; 2,
application of carbachol; sequential exposure of drugs according to the
Freiburg protocol [11]). CF was suspected in all four male patients (current
age: A, 31 years; B, 45 years; C, 15 years; D: 38 years) because of severe
chronic lung disease as it is typically seen in CF: persistent chest radiograph
abnormalities, chronic airway obstruction, persistent colonization with
Staphylococcus aureus (patients A, B, C) and Pseudomonas aeruginosa
(patients B, D), nasal polyps and digital clubbing (patients B, D). All four
patients are exocrine PS. Patients A and D are infertile, patient B is the
father of two healthy children. Pilocarpine iontophoresis sweat tests yielded
(Cl) concentrations in the range of 50–90 mval/l for patients B, C, D and
of 90–110 mval/l for patient A. Mutation analysis of the promoter region
and of all exon and flanking intron sequences (patients A–D) and search
for deletions by pulsed-field gel electrophoresis (patients A and B) did not
reveal any disease-causing lesion in the CFTR gene of the four patients.
ICM provided evidence for CFTR dysfunction in patients B and C: the
DIDS-insensitive chloride secretory responses were significantly lower than
in non-CF controls (upper CF range, residual CFTR activity). In contrast,
normal secretory responses typical for non-CF controls were seen upon the
addition of carbachol or histamine in patients A and D.
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and is consistent with CF. Examples and their interpretation
are shown in Figs. 2 and 3.6. Limitations and pitfalls of the ICM technique
The most frequent experimental complications observed
in ICM are (1) an improper orientation of the biopsy on
the mounting disk (mucosa down, or folded); (2) current
drift resulting from edge damage; (3) excessive mucus
accumulation. Condition (1) can be diagnosed unequivo-
cally by monitoring the Isc response to a second addition
of amiloride or carbachol to the opposite compartment of
the chamber (S and M side, respectively); because the
amiloride target, the epithelial Na+ channel (ENaC) chan-
nel, is accessible only from the M side, whereas the
carbachol target, the muscarinic receptor, is more readily
accessible from the S side, a fast current response to S
amiloride, or to M carbachol is a clear sign of a reversed
orientation of the biopsy in the chamber (Fig. 4). Because
conditions (2) and (3) result in an underestimation of the
tissue response, the intestinal current (IC) tracing of the
biopsy with the highest Cl secretory response is routinely
selected for the computations.
An intrinsic complication in interpretation of the ICM
data is the simultaneous activation of Cl and K+ secretory
pathways in the colonocytes by both Ca2 +-and cAMP-
linked secretagogues. Considering the present lack of
highly specific inhibitors for either one of these pathways
(e.g. CFTR inhibitors or blockers of the apical K+ chan-
nels), the net current response is invariably a summation of
Cl and K+ currents and does not solely reflect a Cl
secretory response. Therefore, a negative Isc response in
CF biopsies cannot be taken as evidence for the complete
absence of CFTR-mediated Cl secretion, it merely
implies that the K+ secretory current is larger than the
residual Cl current. Moreover it should be kept in mind
that the IC response is not proportional to the amount of
CFTR in the apical membrane of the colonocyte, except atFig. 4. Establishing the orientation of the biopsy. This figure shows a
correctly mounted (left tracing) and a folded biopsy (right tracing). Two
biopsies were mounted in parallel in two Ussing chambers. Amiloride was
added to the left side of the Ussing chambers at time points ‘‘a’’ and ‘‘A’’,
and to the right side at time points ‘‘b’’ and ‘‘B’’, respectively. The
orientation of the left biopsy is indicated by the absence of a reaction to
amiloride when added to the left side (‘‘a’’, S side of the biopsy) and a
response to amiloride when added to the right side (‘‘b’’, M side of the
biopsy). The right biopsy is folded as it reacts to amiloride applied to both
sides of the Ussing chamber (‘‘A’’ and ‘‘B’’).
H.R. De Jonge et al. / Journal of Cystic Fibrosis 3 (2004) 159–163 163very low levels of CFTR protein expression ( < 10–15% of
normal; cf. Ref. [9]). At higher values, the CFTR conduc-
tance is no longer rate-limiting for the transepithelial
transport of Cl, as is evident from the failure of ICM
to detect the expected f 50% loss of CFTR protein in CF
heterozygotes [10]. Therefore it can be anticipated that
CFTR mutations resulting in less than 80–85% loss of
CFTR expression/function at the level of the colonocytes,
would escape detection by the ICM technique.Acknowledgements
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